Sphingolipids in Cancer, Volume 140, the latest release in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. Topics discussed in this updated volume include Mechanisms of ceramide-dependent cancer cell death, Sphingolipids as regulators of autophagy and endocytic trafficking, The role and function of sphingomyelin biosynthesis in the development of cancer, Neutral sphingomyelinases in cancer: Friend or foe?, Sphingolipid rendezvous at the crossroad of NAFLD and senescence, Ceramide signaling and p53 pathways, Sphingolipid regulation of RNA Biology in cancer phenotypes, The role of ceramide-1-phosphate in tumor cell survival and dissemination, and more.
- Provides information on cancer research, with this release focusing on sphingolipids
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.
- Mechanisms of ceramide-dependent cancer cell death
- Sphingolipids as regulators of autophagy and endocytic trafficking
- Role and function of sphingomyelin biosynthesis in the development of cancer
- Neutral sphingomyelinases in cancer: friend or foe?
- Ceramide and exosomes: a novel target in cancer biology and therapy
- Sphingolipids at the crossroads of NAFLD and senescence
- Ceramide signaling and p53 pathways
- The role of ceramide 1-phosphate in tumor cell survival and dissemination
- The onus of sphingolipid enzymes in cancer drug resistance
- Interdiction of sphingolipid metabolism revisited: focus on prostate cancer
- Targeting sphingosine kinases for the treatment of cancer
- Novel sphingolipid-based cancer therapeutics in the personalized medicine era
- Side effects in cancer therapy: are sphingolipids to blame?
Rose Nganga, Natalia Oleinik and Besim Ogretmen
Megan M. Young and Hong-Gang Wang
Giovanni D’Angelo, Sitapriya Moorthi and Chiara Luberto
Christopher J. Clarke
Ahmed Elsherbini and Erhard Bieberich
Kristen Jeffries and Natalia Krupenko
Samy A.F. Morad and Myles C. Cabot
Christina Voelkel-Johnson, James S. Norris and Shai White-Gilbertson
Clayton S. Lewis, Christina Voelkel-Johnson and Charles D. Smith
Jeremy Shaw, Pedro Costa-Pinheiro, Logan Patterson, Kelly Drews, Sarah Spiegel and Mark Kester
Falak Patel and Stefka D. Spassieva
- No. of pages:
- © Academic Press 2018
- 9th August 2018
- Academic Press
- Hardcover ISBN:
Professor Charles E. Chalfant heads up the Chalfant Laboratory and is the director of the Lipidomic Facility at Virgina Commonwealth University. The Chalfant laboratory is currently focused on two major areas of cell signaling and human pathophysiologies: 1) lipid and oncogenic regulation of alternative splicing; and 2) the regulation of eicosanoid synthesis in inflammation and cancer.
Director of Lipidomics Facility, Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA
Paul B. Fisher, M.Ph., Ph.D., is an accomplished molecular biologist investigating the mechanisms involved in cancer development and progression in order to define improved methods for cancer prevention, detection and therapy. Fisher pioneered a powerful technique to study gene expression in specific tissues or cell types known as subtraction hybridization, which he has used to identify genes involved in many important and medically relevant physiological processes including cancer, neurodegeneration and infectious diseases. Studies in his laboratory focus on understanding the molecular and biochemical reasons for cancer development with a specific focus on understanding how cancers spread, a process called metastasis. The ultimate aim is to use this collected knowledge to bring new, more effective prevention techniques, diagnostic approaches and therapies from the laboratory bench to the patient’s bedside. This is epitomized by his studies involving mda-7/IL-24, a gene that was discovered in his laboratory and has displayed significant clinical efficacy in a phase 1 clinical trial when injected directly into advanced cancers using a form of viral gene therapy. Using a novel cancer terminator virus, Ad.5/3-CTV, that is designed to replicate only within cancer cells while delivering the immune-modulating and toxic mda-7/IL-24 gene, Fisher and his clinical colleagues are developing a clinical trial in patients with glioblastoma multiforme, the most common and deadly form of brain cancer. Fisher has been consistently funded by the National Institutes of Health (NIH) over the past 35 years and is among the top 5 percent of NIH funded investigators during this period. He has published over 500 primary papers and reviews, served on numerous NIH study sections and government and private grant review panels and has over 55 issued patents. He is the recipient of multiple National Cancer Institute (NCI) Program Project Grants; investigator initiated R01 grants from the NIH, NCI and National Institute of General Medical Sciences (NIGMS); private foundation grants from the National Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation; and an Institutional Research and Academic Career Development Award from the NIH focusing on preparing students from groups underrepresented in the sciences for research careers. Fisher is Professor and Chair of the Department of Human and Molecular Genetics at the Virginia Commonwealth University (VCU) School of Medicine, Founding Director of the VCU Institute of Molecular Medicine and Thelma Newmeyer Corman Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey Cancer Center.
VCU Institute of Molecular Medicine, VA, USA